SCHEMBL2063319

SCHEMBL2063319

Cc1csc(-c2cn3cc(-c4ccc(F)c(CO)c4F)ccc3n2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.66
▸ ALDH1A3 P47895 4/20 0.38
▸ CYP2C9 P11712 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ NPC1 O15118 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TGFBR1 P36897 2/20 0.36
▸ LRRK2 Q5S007 2/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM5C P41229 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431622 0.88 NR4A2 (0.49) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL3406985 0.83 NR4A2 (0.68) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL3431357 0.82 NR4A2 (0.67) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL2062962 0.82 NR4A2 (0.79) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL3430036 0.82 NR4A2 (0.79) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL3432150 0.81 NR4A2 (0.74) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL2064134 0.80 NR4A2 (0.84) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL3433288 0.80 NR4A2 (0.72) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL2063035 0.80 NR4A2 (0.72) NR4A2ALDH1A3CYP2C9KCNH2NPC1
SCHEMBL2064903 0.80 NR4A2 (0.75) NR4A2ALDH1A3CYP2C9KCNH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 — — EP claimed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 — — US claimed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 — — EP claimed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 — — US claimed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US claimed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US claimed
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 — — EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 — — US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 — — US disclosed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 — — EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 — — US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 — — US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 — — EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885ALDH1A3 1191/4885CYP2C9 451/4885
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1531/4885ALDH1A3 1255/4885CYP2C9 408/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885ALDH1A3 1191/4885CYP2C9 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback